Wendy Cheng

Vice President
Wendy Cheng



Ph.D. and M.P.H., epidemiology, Columbia University; B.S., psychobiology, University of California, Los Angeles

Summary of Experience

Dr. Cheng specializes in applying epidemiologic methods to assess the causal relationship of therapeutic agents with health and safety outcomes in observational studies. Her experience includes new drug application (NDA) contingency studies and post-authorization safety studies (PASS) for regulatory bodies; natural history studies; and real-world evidence development across multiple therapeutic areas. Dr. Cheng has particular expertise in applying advanced methodologies to address complex health care research challenges. She has used machine learning and other predictive modeling techniques, including latent class analysis to identify cost clusters in disease patient population, group-based trajectory analysis to identify disease prognosis patterns, and rule-based approaches to diagnostic algorithms. Dr. Cheng has collected and utilized data from administrative insurance claims, large patient and physician surveys, clinical trials, electronic medical records, longitudinal observational studies, and site-based and panel-based medical chart reviews. She has conducted studies in more than 10 countries and published her research in numerous medical journals. Prior to joining Analysis Group, Dr. Cheng served as a research scientist at Columbia University and worked as a biostatistician in the Clinical Trials Network of the National Institute on Drug Abuse.

Read Wendy's profile

Selected Publishing


  • August 24, 2019

    Analysis Group to Present at ICPE 2019

    Event: 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management
    Host: The International Society for Pharmacoepidemiology (ISPE)